Welcome to our dedicated page for Jade Biosciences news (Ticker: JBIO), a resource for investors and traders seeking the latest updates and insights on Jade Biosciences stock.
Jade Biosciences develops monoclonal antibody therapies for autoimmune diseases, with company updates centered on clinical execution, pipeline expansion, and financing. Its lead program, JADE101, targets APRIL and is being developed for immunoglobulin A nephropathy; additional programs include JADE201, a half-life extended afucosylated anti-BAFF receptor antibody, and JADE301, an antibody program in preclinical development.
Recurring news includes financial results, corporate updates, clinical and biomarker data presentations, research conference participation, private placement financing, equity inducement grants, and leadership changes tied to the company's research and development organization.
Jade Biosciences (Nasdaq: JBIO) closed a public offering of 11,500,000 common shares, including 1,500,000 from full exercise of underwriters’ option, at $15.00 per share.
The deal generated $172.5 million in gross proceeds to fund clinical trials, preclinical studies, manufacturing, R&D, capital spending, and general corporate purposes.
Jade Biosciences (Nasdaq: JBIO) priced a public offering of 10,000,000 common shares at $15.00 per share, for expected gross proceeds of $150 million before expenses. Underwriters have a 30-day option for up to 1,500,000 extra shares.
According to Jade Biosciences, net proceeds plus existing cash will fund clinical trials, preclinical studies, manufacturing, R&D, capital expenditures, working capital and general corporate purposes. The offering is expected to close on June 5, 2026, subject to customary conditions.
Jade Biosciences (Nasdaq: JBIO) plans a proposed underwritten public offering of common stock and, for certain investors, pre-funded warrants to buy common shares. All securities will be sold by Jade, with underwriters receiving a 30-day option for up to 15% additional securities. Proceeds are intended to fund clinical trials, preclinical studies, manufacturing, R&D, capital spending, working capital and general corporate purposes.
Jade Biosciences (Nasdaq: JBIO) reported positive interim Phase 1 results for JADE101, an anti-APRIL antibody for IgA nephropathy. A single 700 mg dose produced ~70% mean IgA reduction sustained at 12 weeks with favorable tolerability and no serious adverse events.
Modeling suggests >70% IgA reductions at steady state using a 700 mg induction followed by 350 mg subcutaneous maintenance dosing every 12 weeks. Phase 2 in IgAN is underway, with interim data expected in 2027 and a Phase 3 trial planned for the first half of 2027.
Jade Biosciences (Nasdaq: JBIO) will host a conference call and webcast on June 1, 2026, at 8:00 a.m. ET to discuss interim Phase 1 healthy volunteer results for JADE101, an anti-APRIL monoclonal antibody in development for IgA nephropathy.
Jade Biosciences (Nasdaq: JBIO) has dosed the first participant in a first-in-human Phase 1 trial of JADE201, an investigational half-life extended afucosylated anti-BAFF receptor monoclonal antibody for rheumatoid arthritis.
The randomized, placebo-controlled single ascending dose study will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and biomarkers, with interim data expected in 2027. Preclinical data showed dose-dependent BAFF-R occupancy, extended half-life, and sustained B cell depletion in non-human primates, supporting potential for infrequent subcutaneous dosing across autoimmune diseases.
Jade Biosciences (Nasdaq: JBIO) dosed the first participant in JUNIPER, its open-label Phase 2 trial of JADE101 for IgA nephropathy (IgAN). The study will enroll about 30 participants and assess safety, urine protein-to-creatinine ratio, renal function, and hematuria.
Interim Phase 2 data are expected in 2027.
Jade Biosciences (Nasdaq: JBIO) reported first quarter 2026 results and provided a corporate update on May 7, 2026. The company held $311.3 million in cash, cash equivalents, and investments as of March 31, 2026, which it expects will fund operations into the first half of 2028.
Key clinical milestones: biomarker-rich Phase 1 JADE101 data to be presented at the 63rd ERA Congress; Phase 2 JADE101 in IgA nephropathy to start in Q2 2026 with interim 2027 data; Phase 1 JADE201 to start in Q2 2026; JADE301 first-in-human expected H1 2027. Management added a new CMO and promoted its R&D president.
Jade Biosciences (Nasdaq: JBIO) announced an inducement equity award tied to the appointment of Edward R. Conner, M.D., as Chief Medical Officer, effective April 22, 2026. The Board granted non-qualified stock options to purchase 500,000 shares under the Inducement Plan.
The options have an exercise price of $25.38 (equal to the April 22, 2026 closing price), vest over four years (25% at one year, then monthly vesting), and the company intends to file a Form S-8 to register the issuable shares.
Jade Biosciences (Nasdaq: JBIO) appointed Edward R. Conner, M.D., as Chief Medical Officer effective April 22, 2026.
Dr. Conner will lead clinical and medical strategy to advance JADE101, initiate a Phase 2 trial in IgA nephropathy, and move JADE201 and JADE301 into the clinic; Andrew King is expanded to President of R&D.
Dr. Conner joins from Ardelyx and previously held senior clinical roles at Third Harmonic Bio, Locanabio, Audentes/Astellas, Sangamo and Genentech; he earned an M.D. from UCSF.